Key result
Dark chocolate (40 g) acutely increased maximal walking distance by 11% (P<0.001) and maximal walking time by 15% (P<0.001) compared to milk chocolate in patients with peripheral artery disease.
Why the study?
Does dark chocolate acutely improve walking autonomy in patients with peripheral artery disease?
RCT (n=20)
Single-blind
Randomly allocated (cross-over)
Does dark chocolate acutely improve walking autonomy in patients with peripheral artery disease?
Effect estimate: 11% increase
p-value: p=<0.001
A single dose of dark chocolate acutely improves maximal walking distance and time in patients with peripheral artery disease, potentially through NOX2-mediated reduction in oxidative stress.
Offers a simple dietary option for acute symptom relief in PAD; extends flavanol evidence to symptomatic claudication.
BACKGROUND: NOX-2, the catalytic subunit of NADPH oxidase, has a key role in the formation of reactive oxidant species and is implicated in impairing flow-mediated dilation (FMD). Dark chocolate exerts artery dilatation via down-regulating NOX2-mediated oxidative stress. The aim of this study was to investigate whether dark chocolate improves walking autonomy in peripheral artery disease (PAD) patients via an oxidative stress-mediated mechanism. METHODS AND RESULTS: FMD, serum levels of isoprostanes, nitrite/nitrate (NOx) and sNOX2-dp, a marker of blood NOX2 activity, maximal walking distance (MWD) and maximal walking time (MWT) were studied in 20 PAD patients (14 males and 6 females, mean age: 69±9 years) randomly allocated to 40 g of dark chocolate (>85% cocoa) or 40 g of milk chocolate (≤35% cocoa) in a single blind, cross-over design. The above variables were assessed at baseline and 2 hours after chocolate ingestion. Dark chocolate intake significantly increased MWD (+11%; P<0.001), MWT (+15%; P<0.001), serum NOx (+57%; P<0.001) and decreased serum isoprostanes (-23%; P=0.01) and sNOX2-dp (-37%; P<0.001); no changes of the above variables were observed after milk chocolate intake. Serum epicatechin and its methylated metabolite significantly increased only after dark chocolate ingestion. Multiple linear regression analysis showed that Δ of MWD was independently associated with Δ of MWT (P<0.001) and Δ of NOx (P=0.018). In vitro study demonstrated that HUVEC incubated with a mixture of polyphenols significantly increased nitric oxide (P<0.001) and decreased E-selectin (P<0.001) and VCAM1 (P<0.001). CONCLUSION: In PAD patients dark but not milk chocolate acutely improves walking autonomy with a mechanism possibly related to an oxidative stress-mediated mechanism involving NOX2 regulation. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01947712.
No takes yet. Share an insight, caveat, or question.
Loffredo et al. (2014) conducted an RCT in Peripheral artery disease (PAD) (n=20). Dark chocolate (>85% cocoa) vs. Milk chocolate (≤35% cocoa) was evaluated on Maximal walking distance (MWD) (11% increase, p=<0.001). Dark chocolate (40 g) acutely increased maximal walking distance by 11% (P<0.001) and maximal walking time by 15% (P<0.001) compared to milk chocolate in patients with peripheral artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: